TOP 2301: Neoadjuvant Chemo for NSCLC

Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301

This study was originally opened on 10/22/2024 as an open-label, two-arm, randomized phase 2 clinical trial, patients with clinical stage 1B-3A non-small cell lung cancer (NSCLC) to receive neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks prior to surgery. As of 7/20/2026, the study was amended to a single arm receiving neoadjuvant chemotherapy, cemiplimab every 3 weeks for 3 cycles and alirocumab every 4 weeks prior to surgery.

The study hypothesis is that the addition of alirocumab to neoadjuvant chemoimmunotherapy will make tumor cells more immunogenic to cytotoxic T cells, resulting in an increase in complete pathologic responses in surgically resected tumor.

Study Overview

• Status: Suspended
• Conditions: Non Small Cell Lung Cancer
• Intervention / Treatment: Drug: Alirocumab; Drug: Cemiplimab; Drug: Chemotherapy

• Study Type: Interventional
• Enrollment (Estimated): 63
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 years.
2. Histological/cytological diagnosis of non-small cell lung cancer (NSCLC). Patient is eligible to enroll in the study based on clinical suspicion of NSCLC but are required to have a histological diagnosis of NSCLC in order to be eligible to receive treatment on study.
3. Clinical stage IB, IIA/IIB, or III (N0-2) amenable to surgical resection.
4. Agrees to research blood collections for study.
5. Deemed a surgical candidate.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. No prior chemotherapy, radiation therapy or biologic/targeted therapy for current diagnosis of lung cancer.
8. Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
9. No active invasive malignancy in the past 2 years other than non-melanoma skin cancer. Cancers that are in-situ are not considered invasive.
10. Signed written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines.
11. Sexually active males and females of reproductive potential must agree to use an appropriate contraceptive method during the study and for 120 days following the last dose of study drug.
12. Females of childbearing potential must test negative for pregnancy within 48 hours prior to any initial study procedure based on a serum pregnancy test. (If subject uses appropriate contraceptive methods from the time of the initial serum pregnancy test, then the subsequent pregnancy test can be done within 72 hours prior to start of study treatment. If appropriate contraceptive measures are not begun immediately with the first serum pregnancy test, then subsequent serum pregnancy tests must be done within 48 hours prior to the start of study treatment.)

13. Adequate organ function defined as:

    1. Absolute neutrophil count (ANC) ≥ 1500 per uL
    2. Platelets ≥ 100,000 per uL
    3. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or growth factor dependency (within 7 days of assessment)
    4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 60 mL/min for subject with creatinine levels > 1.5 x ULN
    5. Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    6. Aspartate aminotransferase (AST) [serum glutamic-oxaloacetic transaminase (SGOT)] and alanine aminotransferase (ALT) [glutamic-pyruvic transaminase (SGPT)]≤ 2.5 x ULN
    7. Albumin ≥ 2.5 mg/dL
    8. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy and within therapeutic range of intended use of anticoagulants
    9. Activated Partial Thromboplastin Time (aPTT) ≤1.5 x ULN unless subject is receiving anticoagulant therapy and within therapeutic range of intended use of anticoagulants

Exclusion Criteria:

1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.
2. Participants with known EGFR mutations, ALK translocation, or ROS1 translocation. If testing is done, an FDA-approved assay should be used.
3. Known history of active TB (Bacillus Tuberculosis).
4. Hypersensitivity to alirocumab or any of its excipients.
5. Concurrent administration of any other anti-tumor therapy.
6. Prior therapy with an anti-PD-1, anti-PD-L-1, or anti-PD-L2 agent.
7. Therapy with an anti-PCSK9 agent within 90 days of study entry.
8. Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
9. Inability to comply with protocol or study procedures.
10. Active infection requiring antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
11. Known history of, or any evidence of active, non-infectious pneumonitis.

12. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or HCV infection; or diagnosis of immunodeficiency. Exceptions:

    1. Patients with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are permitted.
    2. Patients with HBV (hepatitis B surface antigen positive) who have controlled infection (serum hepatitis B virus DNA polymerase chain reaction (PCR) that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted.
    3. Patients who are HCV antibody positive (HCV Ab +) who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
13. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc.) is not considered a form of systemic treatment. Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g. Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis).
14. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
15. Known additional invasive malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy in situ cervical cancer.
16. Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of study treatment.
17. Major surgery (other than definitive lung cancer surgery) within two weeks of study or other serious concomitant disorders that in the opinion of the investigator would compromise the safety of the patient or compromise the patient's ability to complete the study.

18. Any non-oncology, live vaccine therapy used for prevention of infectious diseases within 30 days prior to start of study treatment.

    Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed. Coronavirus Disease 2019 (COVID-19) vaccines are also allowed.

19. Myocardial infarction having occurred less than 6 months prior to study enrollment, any known uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications. Patients with coronary artery disease treated with surgery and/or stent > 6 months ago, if stable without symptomatic angina pectoris, active ischemia are eligible.
20. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
21. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either psychiatric or physical (e.g., infectious) illness.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A; Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles with alirocumab (PCSK9 inhibitor) every 4 weeks prior to surgery.	Drug: Alirocumab; 300 mg subcutaneously every 4 weeks prior to surgery; Drug: Cemiplimab; 350mg IV every 3 weeks prior to surgery; Drug: Chemotherapy; Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
Experimental: Arm B; Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles without alirocumab (PCSK9 inhibitor) prior to surgery. This ARM was closed as of 7/20/2026	Drug: Cemiplimab; 350mg IV every 3 weeks prior to surgery; Drug: Chemotherapy; Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the pathologic complete response (pCR) rate for neoadjuvant chemotherapy plus cemiplimab with alirocumab.	Pathologic complete response (pCR) is defined as a lack of all signs of cancer in tissue samples removed during surgery or biopsy after neoadjuvant therapy.	2 years
Determine the safety, and tolerability of neoadjuvant chemotherapy and cemiplimab with alirocumab in early-stage non-small cell lung cancer	Safety will be determined by evaluating the severe adverse events rate for the experimental therapy.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by overall survival (OS)	Overall survival (OS) is the length of time that a patient lives following treatment	2 years
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by Objective Response Rate (ORR)	ORR is defined as Complete Response (CR) + Partial Response (PR) as determined per RECIST 1.1 for the surgical outcome	2 years
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by Disease Control Rate (SD)	Disease Control Rate (SD) is defined as the time from treatment initiation to disease progression (first disease recurrence or death, whichever comes first) after surgery	2 years
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by Duration of Response (DOR)	Duration of Response (DOR) is defined as the time from treatment initiation to disease recurrence (first disease recurrence or death, whichever comes first) after surgery	2 years
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by Event Free Survival (EFS)	Event Free Survival (EFS) is defined as the time from study enrollment to event recurrence (first disease progression or death, whichever comes first) after surgery	2 years
Assess the preliminary efficacy of chemotherapy and cemiplimab with alirocumab as determined by Major Pathologic Response (MPR)	Major Pathologic Response (MPR) is determined by calculating percentage of viable tumor cells in the resected tumor	Surgery

Collaborators and Investigators

• Sponsor: Duke University
• Collaborators: Regeneron Pharmaceuticals
• Investigators: Principal Investigator: Neal Ready, MD, PhD, Duke University

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2025
• Primary Completion (Estimated): October 30, 2028
• Study Completion (Estimated): October 30, 2029

Study Registration Dates

• First Submitted: April 22, 2024
• First Submitted That Met QC Criteria: April 22, 2024
• First Posted (Actual): April 26, 2024

Study Record Updates

• Last Update Posted (Actual): August 24, 2026
• Last Update Submitted That Met QC Criteria: August 21, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Therapeutics; Drug Therapy; cemiplimab; alirocumab
• Other Study ID Numbers: Pro00114645

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No